Preoperative intensity modulated radiation therapy for retroperitoneal sarcoma.

Area of Science:

• Radiation Oncology
• Surgical Oncology
• Medical Oncology

Background:

• Retroperitoneal sarcomas (RSTS) are rare malignancies requiring multimodal treatment.
• Intensity modulated radiation therapy (IMRT) allows for precise radiation delivery, potentially improving outcomes for RSTS.
• Assessing the efficacy and toxicity of neoadjuvant IMRT in RSTS is crucial for treatment planning.

Purpose of the Study:

• To evaluate the outcomes and toxicities of patients with RSTS treated with neoadjuvant external beam radiation (EBRT) using IMRT.
• To identify factors influencing local control and overall survival in this patient cohort.

Main Methods:

• Retrospective analysis of 21 patients with primary or recurrent RSTS treated with preoperative IMRT (2005-2011).
• Kaplan-Meier method used for overall survival (OS) and local recurrence-free survival (LRFS) analysis.
• Toxicity assessment using CTCAE v. 3 criteria for acute and chronic adverse events.

Main Results:

• Five-year OS was 51%, with 2- and 3-year OS at 66%.
• Five-year LRFS was 51%, with 2- and 3-year LRFS at 57%.
• Predictive factors for local control included negative margins, smaller tumor size (<15 cm), liposarcoma histology, and primary disease status. Grade 1 histology correlated with better OS.

Conclusions:

• Neoadjuvant IMRT is well-tolerated in RSTS patients, with manageable acute and chronic toxicities.
• Local recurrences remain a significant challenge, suggesting a need for dose escalation strategies.
• Optimizing treatment for RSTS requires balancing local control with acceptable toxicity.